Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Both Expanded and Uncultured Mesenchymal Stem Cells from MDS Patients Are Genomically Abnormal, Showing a Specific Genetic Profile for the 5q- Syndrome.

Olga López Villar, MD, Juan LuíS. García, PhD, Fermín. M Sánchez Guijo, MD, PhD, Cristina Robledo, Pilar Hernandez Campo, PhD, Maria Diez Campelo, MD, PhD, Sandra Muntion, Jose Antonio Pérez Simón, MD, PhD, J.F. San Miguel, MD, PhD, MaríA. Consuelo Del Cañizo, MD, PhD

Blood (2008) 112 (11): 1650.

https://doi.org/10.1182/blood.V112.11.1650.1650

Published: 2008

Journal Articles

DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

Enrique M Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San-Segundo, David Vilanova, Lucía López-Corral, Juan Carlos Montero, Teresa Hernández-Iglesias, Enrique de Álava, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Atanasio Pandiella, J.F. San Miguel, MD, PhD

Blood (2008) 112 (11): 245.

https://doi.org/10.1182/blood.V112.11.245.245

Published: 2008

Journal Articles

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Maria-Victoria Mateos, Albert Oriol, Joaquín Martínez, Ma Teresa Cibeira, Raquel de Paz, Ma José Terol, José García-Laraña, Enrique Bengoechea, Rafael Martínez, Alejandro Martin, Felipe de Arriba, Luis Palomera, José Hernández, Jose-Luis Bello, María-Luisa Martín, Yolanda González, Joan Blade, MD, Juan José Lahuerta, J.F San Miguel, MD, PhD

Blood (2008) 112 (11): 651.

https://doi.org/10.1182/blood.V112.11.651.651

Published: 2008

Journal Articles

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

Enrique M. Ocio, MD, PhD, David Vilanova, BS, Laura San-Segundo, BS, Patricia Maiso, BS, PhD, Mercedes Garayoa, BS, PhD, Peter Atadja, Atanasio Pandiella, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1514.

https://doi.org/10.1182/blood.V110.11.1514.1514

Published: 2007

Journal Articles

The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.

Enrique M. Ocio, MD, PhD, Patricia Maiso, BS, PhD, Mercedes Garayoa, BS, PhD, Marc Dupuis, Atanasio Pandiella, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1515.

https://doi.org/10.1182/blood.V110.11.1515.1515

Published: 2007

Journal Articles

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

M. Alcoceba, L. Marin, A. Balanzategui, M.E. Sarasquete, PhD, P. Martin-Jimenez, PhD, M.C. Chillon, PhD, M. Vargas, R. Corral, MD, E. Perez, MD, J. Fernandez-Calvo, MD, PhD, A. Martinez, MD, PhD, J.M. Hernandez, MD, PhD, Joan Blade, MD, PhD, J.J. Lahuerta, MD, PhD, R. Garcia-Sanz, MD, PhD, M. Gonzalez, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1481.

https://doi.org/10.1182/blood.V110.11.1481.1481

Published: 2007

Journal Articles

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

María-Victoria Mateos, MD, PhD, Juán-José Lahuerta, MD, PhD, Anna Sureda, MD, PhD, Javier de la Rubia, MD, PhD, Ramón García-Sanz, MD, PhD, Rafael Martínez, MD, PhD, José García-Laraña, MD, PhD, Felipe de Arriba, MD, PhD, Jose-María Ribera, MD, PhD, Miguel-Teodoro Hernández, MD, PhD, Lourdes Escoda, MD, PhD, Dolores Carrera, MD, PhD, Joan Besalduch, MD, PhD, B. Hernández, MD, PhD, P. Fernández, MD, PhD, Joan Blade, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 937.

https://doi.org/10.1182/blood.V110.11.937.937

Published: 2007

Journal Articles

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

Fermin M. Sanchez-Guijo, MD, PhD, Eva Lumbreras, BSc, Patricia Morais, BSc, Juan-Luis Garcia, PhD, Norma C. Gutierrez, MD, PhD, J.F. San Miguel, MD, PhD, Consuelo del Canizo, MD, PhD, Jesus M. Hernandez-Rivas, MD, PhD

Blood (2007) 110 (11): 2947.

https://doi.org/10.1182/blood.V110.11.2947.2947

Published: 2007

Journal Articles

The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs.

Patricia Maiso, Enrique M. Ocio, MD,PhD, Mercedes Garayoa, PhD, Mark A. Pearson, MD,PhD, Atanasio Pandiella, MD,PhD, J.F. San Miguel, MD,PhD

Blood (2006) 108 (11): 2599.

https://doi.org/10.1182/blood.V108.11.2599.2599

Published: 2006

Journal Articles

Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.

Enrique Colado, MD, Jesus Martin, MD, Maria-Belen Vidriales, MD,PhD, Atanasio Pandiella, MD,PhD, Dixie-Lee Esseltine, MD,FRCPC, Jose J. Perez, Enrique M. Ocio, MD,PhD, J.F. San Miguel, MD,PhD

Blood (2006) 108 (11): 1989.

https://doi.org/10.1182/blood.V108.11.1989.1989

Published: 2006

Journal Articles

New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.

Ernesto Perez-Persona, MD, María-Belén Vidriales, MD,PhD, Gema Mateo, PhD, Ramón Garcia Sanz, MD,PhD, Marivi Mateos, MD,PhD, Alfonso Garcia de Coca, MD, Josefina Galende, MD,PhD, Guillermo Martin-Nunez, MD, Jose M. Alonso, MD, Natalia Heras, MD, Jose M. Hernandez, MD,PhD, Alejandro Martin, MD,PhD, Consuelo Lopez-Berges, MD,PhD, Alberto Orfao, MD,PhD, J.F. San Miguel, MD,PhD

Blood (2006) 108 (11): 3517.

https://doi.org/10.1182/blood.V108.11.3517.3517

Published: 2006

Journal Articles

Identification of Neoplastic Infiltration of the Cerebrospinal Fluid (CSF) in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (B-NHL) without Clinical Evidence of Leptomeningeal Disease: A Comparative Analysis of the Utility of Flow Cytometry (FCM) Versus Conventional Cytology (CC).

A. Orfao, MD, PhD, S. Quijano, MSc, A. Lopez, BSc, G. Deben, MD, A. Salar, MD, C. Poderos, MD, J.M. Sancho, MD, C. Vallejo, MD, J. Arias, MD, J.A. Garcia, MD, F. Capote, MD, M. Morado, MD, C. Nicolas, MD, J. Briones, MD, S. Fernandez, MD, A. Carmona, MD, L. Vazquez, MD, J.F. San Miguel, MD, PhD

Blood (2006) 108 (11): 4605.

https://doi.org/10.1182/blood.V108.11.4605.4605

Published: 2006

Journal Articles

Minimal Residual Disease Monitoring after Reduced Intensity Conditioning (RIC) Allogeneic Transplantation: May Help To Individualize Post-Transplant Immunotherapeutic Strategies.

Maria Diez-Campelo, MD, PhD, Jose A. Perez-Simon, MD, PhD, Jose J. Perez, Dolores M. Caballero, MD, PhD, Belen Vidriales, MD, PhD, Miguel Alcoceba, Lourdes Vazquez, MD, PhD, Marcos Gonzalez, MD, PhD, Consuelo M. Canizo, MD, PhD, Consuelo M. Lopez-Berges, MD, PhD, Jesus Lopez-Fidalgo D, J.F. San Miguel, MD, PhD

Blood (2005) 106 (11): 5397.

https://doi.org/10.1182/blood.V106.11.5397.5397

Published: 2005

Journal Articles

Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.

J.A. Perez-Simon, MD, PhD, R. Martino, MD, PhD, R. de la Camara, MD, PhD, J. Perez de Oteiza, MD, PhD, J.M. Moraleda, MD, PhD, M. Diez-Campelo, MD, PhD, A. Sureda, MD, PhD, A. Alegre, MD, PhD, J. Sierra, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2005) 106 (11): 5312.

https://doi.org/10.1182/blood.V106.11.5312.5312

Published: 2005

Journal Articles

Symptomatic and Indolent Waldenström’s Macroglobulinemia Display Different Biological and Cytogenetic but Not Immunophenotypic Characteristics.

Enrique M. Ocio, MD, Gema Mateo, MD PhD, Belen Vidriales, MD PhD, Consuelo Lopez-Berges, MD PhD, Norma C. Gutierrez, MD PhD, Jesus M. Hernandez, MD PhD, Fermin M. Sanchez-Guijo, MD PhD, Maria J. Moro, MD, Jose Hernandez, MD, Javier Fernandez-Calvo, MD, Javier Garcia-Frade, MD PhD, Alberto Orfao, MD PhD, J.F. San Miguel, MD PhD

Blood (2004) 104 (11): 3654.

https://doi.org/10.1182/blood.V104.11.3654.3654

Published: 2004

NARROW

Both Expanded and Uncultured Mesenchymal Stem Cells from MDS Patients Are Genomically Abnormal, Showing a Specific Genetic Profile for the 5q- Syndrome.

DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs.

Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.

New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.

Identification of Neoplastic Infiltration of the Cerebrospinal Fluid (CSF) in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (B-NHL) without Clinical Evidence of Leptomeningeal Disease: A Comparative Analysis of the Utility of Flow Cytometry (FCM) Versus Conventional Cytology (CC).

Minimal Residual Disease Monitoring after Reduced Intensity Conditioning (RIC) Allogeneic Transplantation: May Help To Individualize Post-Transplant Immunotherapeutic Strategies.

Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.

Symptomatic and Indolent Waldenström’s Macroglobulinemia Display Different Biological and Cytogenetic but Not Immunophenotypic Characteristics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only